Experimental treatments involving SPM supplementation have been shown to counteract declines in hippocampal SPM levels, diminish inflammatory cytokines, reduce glial activation, and mitigate Aβ and tau pathology in AD mouse models (Weiner et al., 2015; Kantarci et al., 2018; Dunn et al., 2015). The gene discussed is MAPT; the disease is Alzheimer disease.